Access and Benefit Sharing Under the Nagoya Protocol-Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk.
- Heinrich M Research Group 'Pharmacognosy and Phytotherapy', UCL School of Pharmacy, University of London, London, United Kingdom.
- Scotti F Research Group 'Pharmacognosy and Phytotherapy', UCL School of Pharmacy, University of London, London, United Kingdom.
- Andrade-Cetto A Laboratorio de Etnofarmacología, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City, Mexico.
- Berger-Gonzalez M Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
- Echeverría J Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
- Friso F Departmento de Investigación, Centro de Rehabilitación de Toxicómanos y de Investigación de Medicinas Tradicionales-Takiwasi, Tarapoto, Peru.
- Garcia-Cardona F Instituto de Investigación de Recursos Biológicos, Alexander von Humboldt, Sede Venado del Oro, Bogotá, Colombia.
- Hesketh A Indigena Biodiversity Limited, Gerrards Cross, United Kingdom.
- Hitziger M Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
- Maake C Institute of Anatomy, University of Zurich, Zurich, Switzerland.
- Politi M Departmento de Investigación, Centro de Rehabilitación de Toxicómanos y de Investigación de Medicinas Tradicionales-Takiwasi, Tarapoto, Peru.
- Spadafora C Centro de Biología Celular y Molecular de Enfermedades (CBCMe), Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Panama City, Panamá.
- Spadafora R Asociación Nacional de Conservación de la Naturaleza (National Association for the Conservation of Nature), Cd. de Panama City, Panamá.
- 2020-06-26
Published in:
- Frontiers in pharmacology. - 2020
Access and Benefit Sharing (ABS)
Nagoya Protocol
benefit sharing
biological resources
natural products
traditional medicine
English
Background
Global challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can be secured. While the Convention on Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the implementation of the Nagoya Protocol (NP) and of new forms of collaboration often remain unresolved, especially in the context of "the fair and equitable sharing of benefits arising from the utilization of genetic resources" (Convention on Biological Diversity, 2011). The vision and the specific implementation of this international treaty vary from country to country, which poses additional challenges.
Aims
Using a case study approach, in this analysis we aim at understanding the specific opportunities and challenges for implementing international collaborations regarding ABS in six Latin American countries-Chile, Colombia, Guatemala, México, Panama, and Peru. Based on that analysis, we provide recommendations for the path ahead regarding international collaborations under ABS agreements in ethnopharmacological research.
Results and Discussions
The implementation of the NP varies in the six countries; and while they are all rich in biodiversity, access and benefit sharing mechanisms differ considerably. There is a need to engage in a consultation process with stakeholders, but this has often come to a halt. Institutional infrastructures to implement national policies are weak, and the level of knowledge about the NP and the CBD within countries remains limited.
Conclusions
Different policies in the six countries result in very diverse strategies and opportunities relating to the equitable use of biodiversity. A long-term strategy is required to facilitate a better understanding of the treaties and the resulting opportunities for a fairer development and implementation of transparent national polices, which currently differ in the six countries. So far, the benefits envisioned by the CBD and the NP remain unfulfilled for all stakeholders involved including local communities.
Global challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can be secured. While the Convention on Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the implementation of the Nagoya Protocol (NP) and of new forms of collaboration often remain unresolved, especially in the context of "the fair and equitable sharing of benefits arising from the utilization of genetic resources" (Convention on Biological Diversity, 2011). The vision and the specific implementation of this international treaty vary from country to country, which poses additional challenges.
Aims
Using a case study approach, in this analysis we aim at understanding the specific opportunities and challenges for implementing international collaborations regarding ABS in six Latin American countries-Chile, Colombia, Guatemala, México, Panama, and Peru. Based on that analysis, we provide recommendations for the path ahead regarding international collaborations under ABS agreements in ethnopharmacological research.
Results and Discussions
The implementation of the NP varies in the six countries; and while they are all rich in biodiversity, access and benefit sharing mechanisms differ considerably. There is a need to engage in a consultation process with stakeholders, but this has often come to a halt. Institutional infrastructures to implement national policies are weak, and the level of knowledge about the NP and the CBD within countries remains limited.
Conclusions
Different policies in the six countries result in very diverse strategies and opportunities relating to the equitable use of biodiversity. A long-term strategy is required to facilitate a better understanding of the treaties and the resulting opportunities for a fairer development and implementation of transparent national polices, which currently differ in the six countries. So far, the benefits envisioned by the CBD and the NP remain unfulfilled for all stakeholders involved including local communities.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.3389/fphar.2020.00765
- PMID 32581783
- Persistent URL
- https://folia.unifr.ch/global/documents/33484
Statistics
Document views: 64
File downloads:
- Full-text: 0